ProMetic and Serono Sign a Development and Collaboration Agreement
Development revenues for ProMetic of up to £550,000 (approx. $C1.3M)
Serono will fund the development of an affinity adsorbent to isolate and purify a protein of interest to Serono. A Mimetic Ligand(TM) will be selected from ProMetic´s Intelligent Combinatorial Libraries and will be designed to enhance Serono´s already rigorous therapeutic purification procedures.
"We are thrilled that Serono, a world leader in recombinant products, has chosen ProMetic´s technology to further enhance its manufacturing and purification processes!, commented Pierre Laurin, President and CEO of ProMetic Life Sciences Inc. !This agreement confirms once again the establishment of ProMetic as a world leader in the plasma and recombinant protein purification market!.
Most read news
Organizations
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.